Cargando…

Artificial intelligence in COVID-19 drug repurposing

Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artif...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yadi, Wang, Fei, Tang, Jian, Nussinov, Ruth, Cheng, Feixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500917/
https://www.ncbi.nlm.nih.gov/pubmed/32984792
http://dx.doi.org/10.1016/S2589-7500(20)30192-8
_version_ 1783583949206847488
author Zhou, Yadi
Wang, Fei
Tang, Jian
Nussinov, Ruth
Cheng, Feixiong
author_facet Zhou, Yadi
Wang, Fei
Tang, Jian
Nussinov, Ruth
Cheng, Feixiong
author_sort Zhou, Yadi
collection PubMed
description Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-7500917
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75009172020-09-21 Artificial intelligence in COVID-19 drug repurposing Zhou, Yadi Wang, Fei Tang, Jian Nussinov, Ruth Cheng, Feixiong Lancet Digit Health Review Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic. The Author(s). Published by Elsevier Ltd. 2020-12 2020-09-18 /pmc/articles/PMC7500917/ /pubmed/32984792 http://dx.doi.org/10.1016/S2589-7500(20)30192-8 Text en © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Zhou, Yadi
Wang, Fei
Tang, Jian
Nussinov, Ruth
Cheng, Feixiong
Artificial intelligence in COVID-19 drug repurposing
title Artificial intelligence in COVID-19 drug repurposing
title_full Artificial intelligence in COVID-19 drug repurposing
title_fullStr Artificial intelligence in COVID-19 drug repurposing
title_full_unstemmed Artificial intelligence in COVID-19 drug repurposing
title_short Artificial intelligence in COVID-19 drug repurposing
title_sort artificial intelligence in covid-19 drug repurposing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500917/
https://www.ncbi.nlm.nih.gov/pubmed/32984792
http://dx.doi.org/10.1016/S2589-7500(20)30192-8
work_keys_str_mv AT zhouyadi artificialintelligenceincovid19drugrepurposing
AT wangfei artificialintelligenceincovid19drugrepurposing
AT tangjian artificialintelligenceincovid19drugrepurposing
AT nussinovruth artificialintelligenceincovid19drugrepurposing
AT chengfeixiong artificialintelligenceincovid19drugrepurposing